Education
About Us
Working with TipRanks
Follow Us
BridgeBio Oncology Therapeutics (BBOT)
NASDAQ:BBOT
Total Valuation
BridgeBio Oncology Therapeutics has a market cap or net worth of $1.00B. The enterprise value is ―.
Market Cap$1.00B
Enterprise Value―
Share Statistics
BridgeBio Oncology Therapeutics has 79,988,686 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding79,988,686
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
BridgeBio Oncology Therapeutics’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is -0.30%.
Return on Equity (ROE)0.04
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)-0.30%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee0.00
Profits Per Employee122.57K
Employee Count62
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of BridgeBio Oncology Therapeutics is ―. BridgeBio Oncology Therapeutics’s PEG ratio is -0.00099.
PE Ratio―
PS Ratio0.00
PB Ratio0.93
Price to Fair Value0.93
Price to FCF-228.69
Price to Operating Cash Flow-252.61
PEG Ratio-0.00099
Income Statement
In the last 12 months, BridgeBio Oncology Therapeutics had revenue of 0.00 and earned -74.28M in profits. Earnings per share was 0.46.
Revenue0.00
Gross Profit0.00
Operating Income-80.86M
Pretax Income-74.28M
Net Income-74.28M
EBITDA-80.66M
Earnings Per Share (EPS)0.46
Cash Flow
In the last 12 months, operating cash flow was -94.74M and capital expenditures -764.00K, giving a free cash flow of -95.51M billion.
Operating Cash Flow-94.74M
Free Cash Flow-95.51M
Free Cash Flow per Share-1.19
Dividends & Yields
BridgeBio Oncology Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.10
52-Week Price Change18.06%
50-Day Moving Average12.07
200-Day Moving Average11.06
Relative Strength Index (RSI)52.38
Average Volume (3m)344.97K
Important Dates
BridgeBio Oncology Therapeutics upcoming earnings date is Nov 12, 2025, After Close (Confirmed).
Last Earnings DateInvalid Date
Next Earnings DateNov 12, 2025
Ex-Dividend Date―
Financial Position
BridgeBio Oncology Therapeutics as a current ratio of 10.40, with Debt / Equity ratio of 0.00%
Current Ratio10.40
Quick Ratio10.40
Debt to Market Cap0.00
Net Debt to EBITDA-0.22
Interest Coverage Ratio0.00
Taxes
In the past 12 months, BridgeBio Oncology Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
BridgeBio Oncology Therapeutics EV to EBITDA ratio is 22.76, with an EV/FCF ratio of -226.47.
EV to Sales0.00
EV to EBITDA22.76
EV to Free Cash Flow-226.47
EV to Operating Cash Flow-226.47
Balance Sheet
BridgeBio Oncology Therapeutics has $468.29M in cash and marketable securities with $2.89M in debt, giving a net cash position of $465.40M billion.
Cash & Marketable Securities$468.29M
Total Debt$2.89M
Net Cash$465.40M
Net Cash Per Share$5.82
Tangible Book Value Per Share$11.34
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for BridgeBio Oncology Therapeutics is $23.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$23.00
Price Target Upside82.68% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast―